drugset / Trial / NCT00386321

Yt90 Zevalin and Combination Chemotherapy (Z-CHOP)in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-cell Lymphoma

NCT00386321

Phase 2 Terminated 10 enrolled Chulalongkorn University Bayer · collab
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether the treatment of Yt90 Zevalin in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone)are effective as first line treatment in patients with bulky stage II or stage III or IV diffuse large B-cell lymphoma

Timeline

Start
2006-04
Primary completion
2007-07
Completion
2010-01

Drugs

EvaluationDrugModalityDoseRoute
Subject ibritumomab tiuxetan Monoclonal antibody